SRC-RAC1 Signaling Drives Drug Resistance to BRAF Inhibition in De-Differentiated Cutaneous Melanomas

Investigators showed that wildtype RAC1 was a critical driver of growth and drug resistance, but only in a subset of melanomas with elevated markers of de-differentiation. Similarly, SRC inhibition also selectively sensitized de-differentiated melanomas to BRAF inhibition.